Antibody Information
General Information of This Antibody
| Antibody ID | ANI0GLXGI |
|||||
|---|---|---|---|---|---|---|
| Antibody Name | Anti-Lysozyme mAb |
|||||
| Antibody Type | Monoclonal antibody (mAb) |
|||||
| Antibody Subtype | Humanized IgG |
|||||
| Antigen Name | . |
Antigen Info | ||||
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
IgG1-ADC-07 [Investigative]
Discovered Using Patient-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 81.28% (Day 22) | |||
| Method Description |
Conjugates of the exemplary antibodies were tested using an established PDX model of esophageal squamous cell carcinoma cell implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once post cell inoculation with 10 mg/kg, i.v., QW*3 of one of the conjugates listed above or with PBS only.
|
||||
| In Vivo Model | Esophageal squamous cell carcinoma PDX model (PDX: ES0204) | ||||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 88.81% (Day 22) | |||
| Method Description |
Conjugates of the exemplary antibodies were tested using an established PDX model of prostate cancer cell implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once post cell inoculation with 10 mg/kg, i.v., QW*3 of one of the conjugates listed above or with PBS only.
|
||||
| In Vivo Model | Prostate cancer PDX model (PDX: PR9586) | ||||
Discovered Using Cell Line-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 37.64% (Day 15) | |||
| Method Description |
Conjugates of the exemplary antibodies were tested using an established xenograft model of SW480 cells implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once post cell inoculation with 10 mg/kg, i.v., QW*3 of one of the conjugates listed above or with PBS only.
|
||||
| In Vivo Model | SW480 CDX model | ||||
| In Vitro Model | Colon adenocarcinoma | SW480 cells | CVCL_0546 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 49.17% (Day 29) | |||
| Method Description |
Conjugates of the exemplary antibodies were tested using an established xenograft model of NCI-H358 cells implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once post cell inoculation with 5 mg/kg, i.v., QW*3 of one of the conjugates listed above or with PBS only.
|
||||
| In Vivo Model | NCI-H358 CDX model | ||||
| In Vitro Model | Minimally invasive lung adenocarcinoma | NCI-H358 cells | CVCL_1559 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 53.80% (Day 18) | |||
| Method Description |
Conjugates of the exemplary antibodies were tested using an established xenograft model of SW480 cells implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once post cell inoculation with 10 mg/kg, i.v., QW*3 of one of the conjugates listed above or with PBS only.
|
||||
| In Vivo Model | SW480 CDX model | ||||
| In Vitro Model | Colon adenocarcinoma | SW480 cells | CVCL_0546 | ||
References
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.